GS-6620

DB15222InvestigationalSmall molecule

GS-6620 is under investigation in clinical trial NCT01316237 (A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection).

Formula / weight: C₂₉H₃₇N₆O₉P · 644.622 g/mol (avg)
Code names: GS-6620

Resolves to

Compound

UNIIWD5DUG7X38CAS1350735-70-4ChEMBLCHEMBL3120793

Structure

InChIKeyYAAQYJCOIFNMKX-RSTNYOGXSA-NSMILESCC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@](C#N)(C2=CC=C3N2N=CN=C3N)[C@](C)(O)[C@@H]1OC(=O)C(C)C)OC1=CC=CC=C1

Targets

P26664Genome polyprotein

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with GS-6620, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account